From the article:
“In a 2024 Science study, researchers performed a high-resolution EM reconstruction of the ultrastructure of a cubic millimeter of human temporal cortex. According to the authors, the reconstruction contains roughly 57,000 cells, about 230 millimeters of blood vessels, and nearly 150 million synapses, comprising 1,400 terabytes of data.”
This website uses a security service to protect against malicious bots. This page is displayed while the website verifies you are not a bot.
Tescan launches the new CLARA™, an ultra-high-resolution SEM designed for nanoscale materials characterization and advanced imaging.
Zahi A. Fayad, PhD, is the Lucy G. Moses Professor of Medical Imaging and Bioengineering at the Icahn School of Medicine at Mount Sinai, where he also serves as Vice Chair for Research in Radiology and holds professorships in Medicine (Cardiology) and AI & Human Health. He is the founding Director of the BioMedical Engineering and Imaging Institute (BMEII), home to one of the nation’s top NIH-funded radiology programs (#2 in 2025 per Blue Ridge rankings). Dr. Fayad also co-leads Mount Sinai’s system-wide Healthspan initiative, coordinating research, clinical, and digital infrastructure to advance precision prevention across the enterprise.
Dr. Fayad is Principal Investigator on multiple major grants, including five NIH-funded projects (3 R01s, 2 P01s) supported by the National Heart, Lung, and Blood Institute, NIAID, and NIDA. A leader in biomedical engineering, his interdisciplinary work integrates advanced imaging, AI, and nanomedicine to drive precision medicine, with research interests focused on how lifestyle stressors — chronic stress, diet, exercise, and sleep — affect long-term cardiovascular and whole-person health.
A Clarivate Highly Cited Researcher since 2018 (~190,000 citations; h-index 142), Dr. Fayad’s seminal contributions include MRI vessel wall imaging (leading to Carotid Plaque-RADS), FDG PET imaging of vascular inflammation, and defining the link between amygdala activity, systemic inflammation, and cardiovascular risk. His research on HDL-based nanoparticles for immune modulation is progressing toward clinical translation for cancer, autoimmune diseases, and transplant rejection — work he is advancing commercially as co-founder of Trained Therapeutix Discovery (TTxD), an early-stage biotech company. He is also a recipient of the Jean Paul II Award for Medicine and Research.
His current projects span cardiovascular, neuroimmune, and transplant-focused research, including stress-induced immune dysregulation; mitral valve prolapse and arrhythmia risk; cocaine use–related carotid atherosclerosis and cognitive impairment; cardiac sarcoidosis therapy monitoring; and immune tracking in organ rejection using nanobiologics — together shifting care upstream toward risk prediction and intervention before clinical events.
He also leads the Mount Sinai DigiTwin Project, an AI-driven platform designed to personalize health optimization by integrating imaging, multi-omics, and real-time physiologic data — initially focused on cardiovascular health and now expanding to whole-person healthspan modeling. Dr. Fayad and colleagues at Mount Sinai are finalists in the $80m XPRIZE Healthspan competition, where they are evaluating a multimodal strategy to meaningfully extend human healthspan.
University of Virginia Comprehensive Cancer Center scientists have developed a promising new experimental approach to targeting glioblastoma, the most common and deadliest brain cancer. The approach could overcome many of the limitations of treatments using existing drugs.
UVA’s Roger Abounader, MD, Ph.D., and colleagues have identified “microRNAs” that can simultaneously suppress multiple malfunctioning genes responsible for glioblastoma’s formation and growth. The scientists use a combination of brain-penetrating nanoparticles, focused ultrasound waves and microbubbles to deliver the miRNAs through the brain’s natural protective barrier—a barrier that typically blocks treatments for tumors and neurodegenerative diseases. The study is published in the Journal of Clinical Investigation.
“This new approach could help target numerous molecules that promote cancer growth, including those for which no drugs exist, at the same time to achieve better therapies,” said Abounader, a professor at UVA’s School of Medicine, Department of Microbiology, Immunology and Cancer Biology, Comprehensive Cancer Center and Center for RNA Science and Medicine. “We are hoping to translate our findings into future clinical trials for patients with glioblastoma and other brain tumors.”
Artificial intelligence faces an energy crisis stemming from a physical traffic jam inside modern computer chips. Processors must continually shuffle data, such as the billions of parameters in complex models, between separate computing and memory nodes. This traffic jam, known as the “von Neumann bottleneck,” hinders the speed and energy efficiency of advanced processors.
To tackle this problem, scientists are developing spintronics, which leverages the electron’s “spin,” or intrinsic magnetic orientation, for more efficient devices. A long-sought milestone in this field is a single device, known as a “spin transistor,” that combines a magnetic bit with a semiconducting switch, allowing it to compute and store data simultaneously.
“The major challenge is understanding how magnetism and electrical current interact in nanoscale devices,” said Boston College physics professor Brian Zhou, whose group led the study. “We developed a single-spin quantum microscope to observe magnetic states inside atomically thin devices as they actively process electrical information.”
QUT researchers have overcome a challenge that has limited next-generation energy-harvesting materials for more than two decades, opening the door to more powerful wearable electronics and new ways of turning wasted heat into electricity. The breakthrough centers on carbon nanotubes, which are flexible, conductive microscopic rods that have long shown promise for wearable technologies but have been difficult to control.
QUT researchers have developed a new molecular strategy that prevents the nanotubes from clumping together and losing performance, enabling a new benchmark for materials that convert heat directly into electricity.
Lead author and QUT PhD researcher Shanshan Zhou said the work established a new way of tackling one of the biggest challenges facing carbon nanotubes.
Metasurfaces are ultrathin optical components engineered with arrays of nanoscale structures that can control light in ways that are difficult for conventional optics. Unlike traditional optical components, which typically rely on their shape and thickness, metasurfaces manipulate light using carefully designed nanostructures patterned on a flat surface.
“Active metasurfaces are extending the capabilities of flat optics by enabling optical functions to be dynamically reconfigured,” says Professor Laura Na Liu, director of the 2nd Physics Institute at the University of Stuttgart. “To tap into this potential, we need to learn how to address individual pixels within a two-dimensional metasurface at visible wavelengths.”
Researchers at the University of Stuttgart have developed an interactively addressable organic metadevice that uses electrically switchable organic materials to dynamically control light. The new platform enables every metasurface pixel to be electronically controlled independently, allowing user commands to be translated directly into dynamic holographic images.
A parasite carried by billions of people worldwide often causes harmful infections during pregnancy and in immunocompromised individuals and is a leading infectious cause of blindness in South America. Once it enters the body, it can rapidly multiply, spreading from one cell to the next.
This single-celled organism, Toxoplasma gondii, belongs to the same group of microbes as the parasite that causes malaria and many other parasites of humans and animals. Cats are Toxoplasma’s main host, but it can infect most warm-blooded mammals, including humans, who typically become infected through contact with cat feces or by consuming undercooked meat or contaminated produce.
The parasite’s ability to survive and spread inside a host depends on its capacity to precisely control which proteins it makes and when. Proteins are the molecular machinery that carries out all of the parasite’s functions, from invading and manipulating host cells to making new copies of the pathogen that spread to other cells and hosts.
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have developed a swallowable nanoscale delivery platform designed to transport therapeutic enzymes through the stomach’s acidic environment and activate a cancer-killing reaction at tumor sites. Early preclinical findings suggest that the approach may offer a new strategy for treating gastric cancer more precisely while reducing damage to healthy tissue.
The preclinical study, published in the Journal of Nanobiotechnology, was led by associate professor Chester Lee Drum, Department of Medicine and the Cardiovascular-Metabolic Disease Translational Research Program (TRP), NUS Medicine, together with co-first authors Dr. Muthu Kumaraswamy Shanmugam and Dr. Girish Vallerinteavide Mavelli, both senior research fellows at the Department of Medicine, NUS Medicine.
Researchers at EMBL Hamburg and collaborators at the Leibniz Research Institute for Molecular Pharmacology (FMP) have mapped how the influenza A virus rewires infected human cells in unprecedented detail. To do this, the researchers used a customized experimental workflow to directly observe how proteins interact inside intact infected cells.
Every year, seasonal influenza kills up to 650,000 people globally and causes serious illness for 3–5 million individuals. The influenza A virus, in particular, has been responsible for several pandemics, including the 1918 Spanish flu pandemic. When this virus infects cells, it releases its genetic material, called RNA, which contains blueprints for a handful of proteins. These proteins then spread throughout the host cell and repurpose its molecular machinery to make more viruses.
Scientists want to understand this process in detail because it would help in designing better drug therapies and vaccines against the flu virus. That’s why it’s crucial to figure out how proteins of the flu virus interact with proteins of host cells and subvert them to meet the virus’s needs. This is the first time scientists have mapped direct virus-host protein contacts at scale inside intact influenza-infected cells, with enough structural detail to model how the proteins fit together.